In a phase II basket trial of the BRAF inhibitor vemurafenib in non-melanoma BRAF V600 mutation-positive solid tumors, two NEC patients had PFS of 7.8 months and 5.7 months, respectively [151]. The gene discussed is BRAF; the disease is neuroendocrine carcinoma.